APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemorrhagic Septicemia Vaccines

Compare research editions
View pricing & licenses

Selected research

Industry Research

Hemorrhagic Septicemia Vaccines Industry Research Report 2026

22 December 2025136 pages

Choose your research edition.

Industry ResearchHemorrhagic Septicemia Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemorrhagic Septicemia Vaccines Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Hemorrhagic Septicemia Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemorrhagic Septicemia Vaccines Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemorrhagic Septicemia Vaccines Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Hemorrhagic Septicemia Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Hemorrhagic Septicemia Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Hemorrhagic Septicemia Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Hemorrhagic Septicemia Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Hemorrhagic Septicemia Vaccines include Zoetis, Vecol, National Veterinary Research Institute, Limor de Colombia, Laboratorios Ovejero, Laboratorios Laverlam, LABIOFAM, Intervac (PVT) Ltd and Institute of Veterinary Preventive Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Hemorrhagic Septicemia Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (m units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/m units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Hemorrhagic Septicemia Vaccines Market by Company

Zoetis

Vecol

National Veterinary Research Institute

Limor de Colombia

Laboratorios Ovejero

Laboratorios Laverlam

LABIOFAM

Intervac (PVT) Ltd

Institute of Veterinary Preventive Medicine

Institute of Animal Health and Veterinary Biologicals

Indian Immunologicals Limited

FATRO

Ceva Santé Animale

C.A. Laboratorios Asociados (CALA)

Brilliant Bio Pharma

Bio-Labs (PVT) Limited

Hemorrhagic Septicemia Vaccines Segment by Type

Oil–adjuvant Vaccines

Aluminum hydroxide-adjuvant Vaccines

Hemorrhagic Septicemia Vaccines Segment by Application

Cattle

Buffaloes

Hemorrhagic Septicemia Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemorrhagic Septicemia Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemorrhagic Septicemia Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemorrhagic Septicemia Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Hemorrhagic Septicemia Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Hemorrhagic Septicemia Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Hemorrhagic Septicemia Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Hemorrhagic Septicemia Vaccines Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Hemorrhagic Septicemia Vaccines Sales (m units) of Manufacturers (2021-2026) Table 7. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Manufacturers (2021-2026) Table 8. Global Hemorrhagic Septicemia Vaccines Revenue of Manufacturers (2021-2026) Table 9. Global Hemorrhagic Septicemia Vaccines Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Hemorrhagic Septicemia Vaccines Average Price (US$/k unit) of Manufacturers (2021-2026) Table 11. Global Hemorrhagic Septicemia Vaccines Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Hemorrhagic Septicemia Vaccines, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Hemorrhagic Septicemia Vaccines, Product Type & Application Table 14. Global Hemorrhagic Septicemia Vaccines Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Hemorrhagic Septicemia Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zoetis Company Information Table 19. Zoetis Business Overview Table 20. Zoetis Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 21. Zoetis Hemorrhagic Septicemia Vaccines Product Portfolio Table 22. Zoetis Recent Developments Table 23. Vecol Company Information Table 24. Vecol Business Overview Table 25. Vecol Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 26. Vecol Hemorrhagic Septicemia Vaccines Product Portfolio Table 27. Vecol Recent Developments Table 28. National Veterinary Research Institute Company Information Table 29. National Veterinary Research Institute Business Overview Table 30. National Veterinary Research Institute Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 31. National Veterinary Research Institute Hemorrhagic Septicemia Vaccines Product Portfolio Table 32. National Veterinary Research Institute Recent Developments Table 33. Limor de Colombia Company Information Table 34. Limor de Colombia Business Overview Table 35. Limor de Colombia Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 36. Limor de Colombia Hemorrhagic Septicemia Vaccines Product Portfolio Table 37. Limor de Colombia Recent Developments Table 38. Laboratorios Ovejero Company Information Table 39. Laboratorios Ovejero Business Overview Table 40. Laboratorios Ovejero Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 41. Laboratorios Ovejero Hemorrhagic Septicemia Vaccines Product Portfolio Table 42. Laboratorios Ovejero Recent Developments Table 43. Laboratorios Laverlam Company Information Table 44. Laboratorios Laverlam Business Overview Table 45. Laboratorios Laverlam Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 46. Laboratorios Laverlam Hemorrhagic Septicemia Vaccines Product Portfolio Table 47. Laboratorios Laverlam Recent Developments Table 48. LABIOFAM Company Information Table 49. LABIOFAM Business Overview Table 50. LABIOFAM Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 51. LABIOFAM Hemorrhagic Septicemia Vaccines Product Portfolio Table 52. LABIOFAM Recent Developments Table 53. Intervac (PVT) Ltd Company Information Table 54. Intervac (PVT) Ltd Business Overview Table 55. Intervac (PVT) Ltd Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 56. Intervac (PVT) Ltd Hemorrhagic Septicemia Vaccines Product Portfolio Table 57. Intervac (PVT) Ltd Recent Developments Table 58. Institute of Veterinary Preventive Medicine Company Information Table 59. Institute of Veterinary Preventive Medicine Business Overview Table 60. Institute of Veterinary Preventive Medicine Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 61. Institute of Veterinary Preventive Medicine Hemorrhagic Septicemia Vaccines Product Portfolio Table 62. Institute of Veterinary Preventive Medicine Recent Developments Table 63. Institute of Animal Health and Veterinary Biologicals Company Information Table 64. Institute of Animal Health and Veterinary Biologicals Business Overview Table 65. Institute of Animal Health and Veterinary Biologicals Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 66. Institute of Animal Health and Veterinary Biologicals Hemorrhagic Septicemia Vaccines Product Portfolio Table 67. Institute of Animal Health and Veterinary Biologicals Recent Developments Table 68. Indian Immunologicals Limited Company Information Table 69. Indian Immunologicals Limited Business Overview Table 70. Indian Immunologicals Limited Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 71. Indian Immunologicals Limited Hemorrhagic Septicemia Vaccines Product Portfolio Table 72. Indian Immunologicals Limited Recent Developments Table 73. FATRO Company Information Table 74. FATRO Business Overview Table 75. FATRO Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 76. FATRO Hemorrhagic Septicemia Vaccines Product Portfolio Table 77. FATRO Recent Developments Table 78. Ceva Santé Animale Company Information Table 79. Ceva Santé Animale Business Overview Table 80. Ceva Santé Animale Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 81. Ceva Santé Animale Hemorrhagic Septicemia Vaccines Product Portfolio Table 82. Ceva Santé Animale Recent Developments Table 83. C.A. Laboratorios Asociados (CALA) Company Information Table 84. C.A. Laboratorios Asociados (CALA) Business Overview Table 85. C.A. Laboratorios Asociados (CALA) Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 86. C.A. Laboratorios Asociados (CALA) Hemorrhagic Septicemia Vaccines Product Portfolio Table 87. C.A. Laboratorios Asociados (CALA) Recent Developments Table 88. Brilliant Bio Pharma Company Information Table 89. Brilliant Bio Pharma Business Overview Table 90. Brilliant Bio Pharma Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 91. Brilliant Bio Pharma Hemorrhagic Septicemia Vaccines Product Portfolio Table 92. Brilliant Bio Pharma Recent Developments Table 93. Bio-Labs (PVT) Limited Company Information Table 94. Bio-Labs (PVT) Limited Business Overview Table 95. Bio-Labs (PVT) Limited Hemorrhagic Septicemia Vaccines Sales (m units), Revenue (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 96. Bio-Labs (PVT) Limited Hemorrhagic Septicemia Vaccines Product Portfolio Table 97. Bio-Labs (PVT) Limited Recent Developments Table 98. Global Hemorrhagic Septicemia Vaccines Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Hemorrhagic Septicemia Vaccines Sales by Region (2021-2026) & (m units) Table 100. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Region (2021-2026) Table 101. Global Hemorrhagic Septicemia Vaccines Sales by Region (2027-2032) & (m units) Table 102. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Region (2027-2032) Table 103. Global Hemorrhagic Septicemia Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Region (2021-2026) Table 105. Global Hemorrhagic Septicemia Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Region (2027-2032) Table 107. North America Hemorrhagic Septicemia Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Hemorrhagic Septicemia Vaccines Sales by Country (2021-2026) & (m units) Table 109. North America Hemorrhagic Septicemia Vaccines Sales by Country (2027-2032) & (m units) Table 110. North America Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Hemorrhagic Septicemia Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Hemorrhagic Septicemia Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Hemorrhagic Septicemia Vaccines Sales by Country (2021-2026) & (m units) Table 114. Europe Hemorrhagic Septicemia Vaccines Sales by Country (2027-2032) & (m units) Table 115. Europe Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Hemorrhagic Septicemia Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Hemorrhagic Septicemia Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Hemorrhagic Septicemia Vaccines Sales by Country (2021-2026) & (m units) Table 119. Asia Pacific Hemorrhagic Septicemia Vaccines Sales by Country (2027-2032) & (m units) Table 120. Asia Pacific Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Hemorrhagic Septicemia Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Hemorrhagic Septicemia Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Hemorrhagic Septicemia Vaccines Sales by Country (2021-2026) & (m units) Table 124. South America Hemorrhagic Septicemia Vaccines Sales by Country (2027-2032) & (m units) Table 125. South America Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Hemorrhagic Septicemia Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Hemorrhagic Septicemia Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Hemorrhagic Septicemia Vaccines Sales by Country (2021-2026) & (m units) Table 129. Middle East and Africa Hemorrhagic Septicemia Vaccines Sales by Country (2027-2032) & (m units) Table 130. Middle East and Africa Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Hemorrhagic Septicemia Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Hemorrhagic Septicemia Vaccines Sales by Type (2021-2026) & (m units) Table 133. Global Hemorrhagic Septicemia Vaccines Sales by Type (2027-2032) & (m units) Table 134. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Type (2021-2026) Table 135. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Type (2027-2032) Table 136. Global Hemorrhagic Septicemia Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Hemorrhagic Septicemia Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Type (2021-2026) Table 139. Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Type (2027-2032) Table 140. Global Hemorrhagic Septicemia Vaccines Price by Type (2021-2026) & (US$/k unit) Table 141. Global Hemorrhagic Septicemia Vaccines Price by Type (2027-2032) & (US$/k unit) Table 142. Global Hemorrhagic Septicemia Vaccines Sales by Application (2021-2026) & (m units) Table 143. Global Hemorrhagic Septicemia Vaccines Sales by Application (2027-2032) & (m units) Table 144. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Application (2021-2026) Table 145. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Application (2027-2032) Table 146. Global Hemorrhagic Septicemia Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Hemorrhagic Septicemia Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Application (2021-2026) Table 149. Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Application (2027-2032) Table 150. Global Hemorrhagic Septicemia Vaccines Price by Application (2021-2026) & (US$/k unit) Table 151. Global Hemorrhagic Septicemia Vaccines Price by Application (2027-2032) & (US$/k unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Hemorrhagic Septicemia Vaccines Distributors List Table 155. Hemorrhagic Septicemia Vaccines Customers List Table 156. Hemorrhagic Septicemia Vaccines Industry Trends Table 157. Hemorrhagic Septicemia Vaccines Industry Drivers Table 158. Hemorrhagic Septicemia Vaccines Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Hemorrhagic Septicemia Vaccines Product Image Figure 5. Global Hemorrhagic Septicemia Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Hemorrhagic Septicemia Vaccines Market Size (2021-2032) & (US$ Million) Figure 7. Global Hemorrhagic Septicemia Vaccines Sales (2021-2032) & (m units) Figure 8. Global Hemorrhagic Septicemia Vaccines Average Price (US$/k unit) & (2021-2032) Figure 9. Oil–adjuvant Vaccines Product Image Figure 10. Aluminum hydroxide-adjuvant Vaccines Product Image Figure 11. Cattle Product Image Figure 12. Buffaloes Product Image Figure 13. Global Hemorrhagic Septicemia Vaccines Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Hemorrhagic Septicemia Vaccines, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Hemorrhagic Septicemia Vaccines Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Hemorrhagic Septicemia Vaccines Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Hemorrhagic Septicemia Vaccines Sales by Region in 2025 Figure 19. Global Hemorrhagic Septicemia Vaccines Revenue by Region in 2025 Figure 20. North America Hemorrhagic Septicemia Vaccines Market Size by Country in 2025 Figure 21. North America Hemorrhagic Septicemia Vaccines Sales Market Share by Country (2021-2032) Figure 22. North America Hemorrhagic Septicemia Vaccines Revenue Market Share by Country (2021-2032) Figure 23. United States Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Mexico Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Hemorrhagic Septicemia Vaccines Market Size by Country in 2025 Figure 27. Europe Hemorrhagic Septicemia Vaccines Sales Market Share by Country (2021-2032) Figure 28. Europe Hemorrhagic Septicemia Vaccines Revenue Market Share by Country (2021-2032) Figure 29. Germany Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Russia Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Spain Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Switzerland Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Sweden Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Poland Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Hemorrhagic Septicemia Vaccines Market Size by Country in 2025 Figure 40. Asia Pacific Hemorrhagic Septicemia Vaccines Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Hemorrhagic Septicemia Vaccines Revenue Market Share by Country (2021-2032) Figure 42. China Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Taiwan Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Hemorrhagic Septicemia Vaccines Market Size by Country in 2025 Figure 51. South America Hemorrhagic Septicemia Vaccines Sales Market Share by Country (2021-2032) Figure 52. South America Hemorrhagic Septicemia Vaccines Revenue Market Share by Country (2021-2032) Figure 53. Brazil Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Chile Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Hemorrhagic Septicemia Vaccines Market Size by Country in 2025 Figure 57. Middle East and Africa Hemorrhagic Septicemia Vaccines Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Hemorrhagic Septicemia Vaccines Revenue Market Share by Country (2021-2032) Figure 59. Egypt Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. South Africa Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Israel Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Türkiye Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. GCC Countries Hemorrhagic Septicemia Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Type (2021-2032) Figure 65. Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Type (2021-2032) Figure 66. Global Hemorrhagic Septicemia Vaccines Price (US$/k unit) by Type (2021-2032) Figure 67. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Application (2021-2032) Figure 68. Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Application (2021-2032) Figure 69. Global Hemorrhagic Septicemia Vaccines Price (US$/k unit) by Application (2021-2032) Figure 70. Hemorrhagic Septicemia Vaccines Value Chain Figure 71. Hemorrhagic Septicemia Vaccines Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Hemorrhagic Septicemia Vaccines Industry Opportunities and Challenges

Scope & coverage.

Types
  • Oil–adjuvant Vaccines
  • Aluminum hydroxide-adjuvant Vaccines
Applications
  • Cattle
  • Buffaloes
Companies covered
  • Zoetis
  • Vecol
  • National Veterinary Research Institute
  • Limor de Colombia
  • Laboratorios Ovejero
  • Laboratorios Laverlam
  • LABIOFAM
  • Intervac (PVT) Ltd
  • Institute of Veterinary Preventive Medicine
  • Institute of Animal Health and Veterinary Biologicals
  • Indian Immunologicals Limited
  • FATRO
  • Ceva Santé Animale
  • C.A. Laboratorios Asociados (CALA)
  • Brilliant Bio Pharma
  • Bio-Labs (PVT) Limited

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Hemorrhagic Septicemia Vaccines Market Size (2021-2032)
  4. 2.2.2 Global Hemorrhagic Septicemia Vaccines Sales (2021-2032)
  5. 2.2.3 Global Hemorrhagic Septicemia Vaccines Market Average Price (2021-2032)
  6. 2.3 Hemorrhagic Septicemia Vaccines by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Oil–adjuvant Vaccines
  9. 2.3.3 Aluminum hydroxide-adjuvant Vaccines
  10. 2.4 Hemorrhagic Septicemia Vaccines by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Cattle
  13. 2.4.3 Buffaloes
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Hemorrhagic Septicemia Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Hemorrhagic Septicemia Vaccines Sales (m units) of Manufacturers (2021-2026)
  3. 3.3 Global Hemorrhagic Septicemia Vaccines Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Hemorrhagic Septicemia Vaccines Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Hemorrhagic Septicemia Vaccines Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Hemorrhagic Septicemia Vaccines, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Hemorrhagic Septicemia Vaccines, Product Type & Application
  8. 3.8 Global Manufacturers of Hemorrhagic Septicemia Vaccines, Established Date
  9. 3.9 Global Hemorrhagic Septicemia Vaccines Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zoetis
  2. 4.1.1 Zoetis Company Information
  3. 4.1.2 Zoetis Business Overview
  4. 4.1.3 Zoetis Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zoetis Hemorrhagic Septicemia Vaccines Product Portfolio
  6. 4.1.5 Zoetis Recent Developments
  7. 4.2 Vecol
  8. 4.2.1 Vecol Company Information
  9. 4.2.2 Vecol Business Overview
  10. 4.2.3 Vecol Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Vecol Hemorrhagic Septicemia Vaccines Product Portfolio
  12. 4.2.5 Vecol Recent Developments
  13. 4.3 National Veterinary Research Institute
  14. 4.3.1 National Veterinary Research Institute Company Information
  15. 4.3.2 National Veterinary Research Institute Business Overview
  16. 4.3.3 National Veterinary Research Institute Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 National Veterinary Research Institute Hemorrhagic Septicemia Vaccines Product Portfolio
  18. 4.3.5 National Veterinary Research Institute Recent Developments
  19. 4.4 Limor de Colombia
  20. 4.4.1 Limor de Colombia Company Information
  21. 4.4.2 Limor de Colombia Business Overview
  22. 4.4.3 Limor de Colombia Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Limor de Colombia Hemorrhagic Septicemia Vaccines Product Portfolio
  24. 4.4.5 Limor de Colombia Recent Developments
  25. 4.5 Laboratorios Ovejero
  26. 4.5.1 Laboratorios Ovejero Company Information
  27. 4.5.2 Laboratorios Ovejero Business Overview
  28. 4.5.3 Laboratorios Ovejero Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Laboratorios Ovejero Hemorrhagic Septicemia Vaccines Product Portfolio
  30. 4.5.5 Laboratorios Ovejero Recent Developments
  31. 4.6 Laboratorios Laverlam
  32. 4.6.1 Laboratorios Laverlam Company Information
  33. 4.6.2 Laboratorios Laverlam Business Overview
  34. 4.6.3 Laboratorios Laverlam Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Laboratorios Laverlam Hemorrhagic Septicemia Vaccines Product Portfolio
  36. 4.6.5 Laboratorios Laverlam Recent Developments
  37. 4.7 LABIOFAM
  38. 4.7.1 LABIOFAM Company Information
  39. 4.7.2 LABIOFAM Business Overview
  40. 4.7.3 LABIOFAM Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 LABIOFAM Hemorrhagic Septicemia Vaccines Product Portfolio
  42. 4.7.5 LABIOFAM Recent Developments
  43. 4.8 Intervac (PVT) Ltd
  44. 4.8.1 Intervac (PVT) Ltd Company Information
  45. 4.8.2 Intervac (PVT) Ltd Business Overview
  46. 4.8.3 Intervac (PVT) Ltd Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Intervac (PVT) Ltd Hemorrhagic Septicemia Vaccines Product Portfolio
  48. 4.8.5 Intervac (PVT) Ltd Recent Developments
  49. 4.9 Institute of Veterinary Preventive Medicine
  50. 4.9.1 Institute of Veterinary Preventive Medicine Company Information
  51. 4.9.2 Institute of Veterinary Preventive Medicine Business Overview
  52. 4.9.3 Institute of Veterinary Preventive Medicine Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Institute of Veterinary Preventive Medicine Hemorrhagic Septicemia Vaccines Product Portfolio
  54. 4.9.5 Institute of Veterinary Preventive Medicine Recent Developments
  55. 4.10 Institute of Animal Health and Veterinary Biologicals
  56. 4.10.1 Institute of Animal Health and Veterinary Biologicals Company Information
  57. 4.10.2 Institute of Animal Health and Veterinary Biologicals Business Overview
  58. 4.10.3 Institute of Animal Health and Veterinary Biologicals Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Institute of Animal Health and Veterinary Biologicals Hemorrhagic Septicemia Vaccines Product Portfolio
  60. 4.10.5 Institute of Animal Health and Veterinary Biologicals Recent Developments
  61. 4.11 Indian Immunologicals Limited
  62. 4.11.1 Indian Immunologicals Limited Company Information
  63. 4.11.2 Indian Immunologicals Limited Business Overview
  64. 4.11.3 Indian Immunologicals Limited Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Indian Immunologicals Limited Hemorrhagic Septicemia Vaccines Product Portfolio
  66. 4.11.5 Indian Immunologicals Limited Recent Developments
  67. 4.12 FATRO
  68. 4.12.1 FATRO Company Information
  69. 4.12.2 FATRO Business Overview
  70. 4.12.3 FATRO Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 FATRO Hemorrhagic Septicemia Vaccines Product Portfolio
  72. 4.12.5 FATRO Recent Developments
  73. 4.13 Ceva Santé Animale
  74. 4.13.1 Ceva Santé Animale Company Information
  75. 4.13.2 Ceva Santé Animale Business Overview
  76. 4.13.3 Ceva Santé Animale Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Ceva Santé Animale Hemorrhagic Septicemia Vaccines Product Portfolio
  78. 4.13.5 Ceva Santé Animale Recent Developments
  79. 4.14 C.A. Laboratorios Asociados (CALA)
  80. 4.14.1 C.A. Laboratorios Asociados (CALA) Company Information
  81. 4.14.2 C.A. Laboratorios Asociados (CALA) Business Overview
  82. 4.14.3 C.A. Laboratorios Asociados (CALA) Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 C.A. Laboratorios Asociados (CALA) Hemorrhagic Septicemia Vaccines Product Portfolio
  84. 4.14.5 C.A. Laboratorios Asociados (CALA) Recent Developments
  85. 4.15 Brilliant Bio Pharma
  86. 4.15.1 Brilliant Bio Pharma Company Information
  87. 4.15.2 Brilliant Bio Pharma Business Overview
  88. 4.15.3 Brilliant Bio Pharma Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Brilliant Bio Pharma Hemorrhagic Septicemia Vaccines Product Portfolio
  90. 4.15.5 Brilliant Bio Pharma Recent Developments
  91. 4.16 Bio-Labs (PVT) Limited
  92. 4.16.1 Bio-Labs (PVT) Limited Company Information
  93. 4.16.2 Bio-Labs (PVT) Limited Business Overview
  94. 4.16.3 Bio-Labs (PVT) Limited Hemorrhagic Septicemia Vaccines Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Bio-Labs (PVT) Limited Hemorrhagic Septicemia Vaccines Product Portfolio
  96. 4.16.5 Bio-Labs (PVT) Limited Recent Developments
5 Global Hemorrhagic Septicemia Vaccines Market Scenario by Region
  1. 5.1 Global Hemorrhagic Septicemia Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Hemorrhagic Septicemia Vaccines Sales by Region: 2021-2032
  3. 5.2.1 Global Hemorrhagic Septicemia Vaccines Sales by Region: 2021-2026
  4. 5.2.2 Global Hemorrhagic Septicemia Vaccines Sales by Region: 2027-2032
  5. 5.3 Global Hemorrhagic Septicemia Vaccines Revenue by Region: 2021-2032
  6. 5.3.1 Global Hemorrhagic Septicemia Vaccines Revenue by Region: 2021-2026
  7. 5.3.2 Global Hemorrhagic Septicemia Vaccines Revenue by Region: 2027-2032
  8. 5.4 North America Hemorrhagic Septicemia Vaccines Market Facts & Figures by Country
  9. 5.4.1 North America Hemorrhagic Septicemia Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Hemorrhagic Septicemia Vaccines Sales by Country (2021-2032)
  11. 5.4.3 North America Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Hemorrhagic Septicemia Vaccines Market Facts & Figures by Country
  16. 5.5.1 Europe Hemorrhagic Septicemia Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Hemorrhagic Septicemia Vaccines Sales by Country (2021-2032)
  18. 5.5.3 Europe Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Hemorrhagic Septicemia Vaccines Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Hemorrhagic Septicemia Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Hemorrhagic Septicemia Vaccines Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Hemorrhagic Septicemia Vaccines Market Facts & Figures by Country
  41. 5.7.1 South America Hemorrhagic Septicemia Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Hemorrhagic Septicemia Vaccines Sales by Country (2021-2032)
  43. 5.7.3 South America Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Hemorrhagic Septicemia Vaccines Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Hemorrhagic Septicemia Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Hemorrhagic Septicemia Vaccines Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Hemorrhagic Septicemia Vaccines Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Hemorrhagic Septicemia Vaccines Sales by Type (2021-2032)
  2. 6.1.1 Global Hemorrhagic Septicemia Vaccines Sales by Type (2021-2032) & (m units)
  3. 6.1.2 Global Hemorrhagic Septicemia Vaccines Sales Market Share by Type (2021-2032)
  4. 6.2 Global Hemorrhagic Septicemia Vaccines Revenue by Type (2021-2032)
  5. 6.2.1 Global Hemorrhagic Septicemia Vaccines Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Hemorrhagic Septicemia Vaccines Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Hemorrhagic Septicemia Vaccines Sales by Application (2021-2032)
  2. 7.1.1 Global Hemorrhagic Septicemia Vaccines Sales by Application (2021-2032) & (m units)
  3. 7.1.2 Global Hemorrhagic Septicemia Vaccines Sales Market Share by Application (2021-2032)
  4. 7.2 Global Hemorrhagic Septicemia Vaccines Revenue by Application (2021-2032)
  5. 7.2.1 Global Hemorrhagic Septicemia Vaccines Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Hemorrhagic Septicemia Vaccines Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Hemorrhagic Septicemia Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Hemorrhagic Septicemia Vaccines Value Chain Analysis
  2. 8.1.1 Hemorrhagic Septicemia Vaccines Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Hemorrhagic Septicemia Vaccines Production Mode & Process
  5. 8.2 Hemorrhagic Septicemia Vaccines Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Hemorrhagic Septicemia Vaccines Distributors
  8. 8.2.3 Hemorrhagic Septicemia Vaccines Customers
9 Global Hemorrhagic Septicemia Vaccines Analyzing Market Dynamics
  1. 9.1 Hemorrhagic Septicemia Vaccines Industry Trends
  2. 9.2 Hemorrhagic Septicemia Vaccines Industry Drivers
  3. 9.3 Hemorrhagic Septicemia Vaccines Industry Opportunities and Challenges
  4. 9.4 Hemorrhagic Septicemia Vaccines Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst